Russotti Gregory 4
4 · Century Therapeutics, Inc. · Filed Feb 4, 2026
Research Summary
AI-generated summary of this filing
Century Therapeutics CTO Gregory Russotti Receives Award
What Happened
Gregory Russotti, Chief Technology and Manufacturing Officer of Century Therapeutics (IPSC), received equity awards on 2026-02-02 consisting of 135,000 restricted stock units (RSUs) and 265,000 derivative awards. Both grants show $0.00 cash paid (they are compensation awards, not open‑market purchases). The RSUs and the derivative award are subject to multi-year vesting schedules described in the filing.
Key Details
- Transaction date: 2026-02-02; Form 4 filed 2026-02-04 (timely filing).
- Awards: 135,000 RSUs (F1) and 265,000 derivative award (listed as derivative; F2 describes an option-style vesting). Cash paid: $0.00 for each line.
- Vesting (per footnotes): RSUs vest 25% on Feb 2, 2027, then quarterly over the following three years and settle in shares (F1). The derivative/option vests 25% on Feb 2, 2027, then the remaining 75% in 36 equal monthly installments, subject to continued service (F2).
- Shares owned after transaction: not specified in the provided excerpt of the filing.
- Filing timeliness: appears timely (filed within the standard Form 4 window).
Context
These are compensation grants (awards), not purchases or sales—no shares were sold or exercised at the time of this filing. The derivative award is subject to vesting and will convert to common stock only as portions vest; continued employment is required to receive vested shares. For retail investors, such grants are routine executive compensation and do not by themselves signal immediate buying or selling activity in the market.
Insider Transaction Report
- Award
Common Stock
[F1]2026-02-02+135,000→ 525,982 total - Award
Stock Option (right to buy)
[F2]2026-02-02+265,000→ 265,000 totalExercise: $1.84Exp: 2036-02-02→ Common Stock (265,000 underlying)
- 92,773(indirect: By Trust)
Common Stock
Footnotes (2)
- [F1]Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs vest 25% on February 2, 2027, with the remaining 75% vesting on a quarterly basis for the three years thereafter, in each case subject the Reporting Person's continued service through the applicable vesting date. The RSUs will be settled on each applicable vesting date in shares of the Issuer's common stock.
- [F2]The option vests 25% on February 2, 2027, with the remaining 75% vesting in 36 equal monthly installments, subject to the Reporting Person's continued service through each applicable vesting date.